State University of New York at Downstate Medical Center

SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory (I&I) diseases, today announced it will host a virtual key opinion leader (KOL) event at 10:00 AM ET on Thursday, October 31, 2024. To register, click here. The event will feature Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), Maryanne Senna, MD (Beth Israel Lahey Health, Harvard Medical School), and Yufang Lu, MD, PhD (Inmagene) who will discuss the potential role of anti-OX40/OX40L monoclonal antibodies (mAbs) in the treatment of atopic dermatitis (AD) and alopecia areata (AA). The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the formal presentations. About Jonathan Silverberg, MD, PhD, MPHJonathan Silverberg, MD, PhD, MPH is an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg completed his undergraduate and medical school training as a part of the highly selective dual B.A./M.D. program at State University of New York Downstate Medical Center, in Brooklyn. Dr. Silverberg also received his doctorate in neuroimmunology and Master of Public Health degree in biostatistics and epidemiology from the State University of New York Downstate Medical Center where he also completed his internship in internal medicine. He completed his residency training in dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Centers in New York, NY and served as Chief Resident during his final year. Dr. Silverberg's area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. He has extensive experience in the advanced management of atopic dermatitis, hand eczema, chronic itch, psoriasis, hidradenitis and many other chronic inflammatory skin disorders. He is also a national expert in allergy patch testing, phototesting and photopatch testing. Dr. Silverberg's research interests include drug development, clinical trial design, biomarkers, dermato-epidemiology, health services research, patient-reported outcomes, comorbidities and burden of itch and inflammatory skin disease and evidence-based dermatology. His publications include more than 600 peer-reviewed articles, abstracts and book chapters. He is also the author of the Clinical Management of Atopic Dermatitis handbook (2018). Dr. Silverberg has also been a local, national and/or international principal investigator for numerous clinical trials for novel treatments in atopic dermatitis and other inflammatory disorders. He has been recognized with several honors, including the Young Leadership Award from the American Dermatological Association in 2017, Teacher of the Year Award in the department of dermatology in 2015, Outstanding Teacher's Award from the Feinberg School of Medicine in 2016, 2017 and 2018, and the inaugural Rajka Award from the International Society for Atopic Dermatitis in 2014. He is an associate editor for the Journal of the American Academy of Dermatology, British Journal of Dermatology and Current Dermatology Reports. Dr. Silverberg is a member of the International Eczema Council, North American Contact Dermatitis Group the American Society of Contact Dermatitis. Dr. Silverberg is also the chair of the annual Revolutionizing Atopic Dermatitis global multidisciplinary conference. About Maryanne Senna, MDMaryanne Senna, MD is a board-certified dermatologist at Beth Israel Lahey Health, and assistant professor of dermatology at Harvard Medical School. Dr. Senna founded and directs the Lahey Hair Loss Center of Excellence and serves as principal of the research unit. Prior to this role, she founded the MGH Hair Loss Clinic and clinical trials unit, which she ran for nearly 10 years. She has held a number of pharmaceutical, device, and foundation appointments. Widely published and recognized for her clinical expertise, teaching, and research, Dr. Senna is frequently invited to speak and give lectures nationally and abroad, and has been quoted in top-tier media publications such as The New York Times and The Atlantic. She has also been featured on multiple news outlets including Good Morning America, and in the HBO Max documentary series Not So Pretty. Dr. Senna is an esteemed member of several professional societies and committees, and is on the board of directors of the Scarring Alopecia Foundation, the American Hair Research Society, and on the medical advisory task force for the National Alopecia Areata Foundation. About Yufang Lu, MD, PhDYufang Lu is the Chief Medical Officer of Inmagene. Dr. Lu is an accomplished physician scientist with more than 20 years of experience in clinical development and medical affairs. She has successfully led clinical development for both small molecules and biologics across diverse therapeutic areas, including dermatology, allergy, gastroenterology, and rheumatology. Prior to Inmagene, Dr. Lu was Vice President of Clinical Development at Celldex, where she drove the advancement of innovative immunology assets, including barzovolimab. During her tenure at Regeneron, she led cross-functional medical teams in the global launches of Dupixent® in atopic dermatitis and asthma. Earlier in her career, she held roles in clinical development and medical affairs at Celgene, Eisai, and GSK. Dr. Lu received her medical degree from Nanjing Medical University with residency training in dermatology and a PhD in toxicology from Texas A&M University. About InmageneInmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor with an extended half-life and pharmacodynamic effect, enabling its potential for once-daily dosing, recently completed the Phase 1 multiple ascending dose (MAD) study and is ready for Phase 2 development. For more information, please visit www.inmagenebio.com. About IMG-007IMG-007 is a humanized anti-OX40 IgG1 mAb, with an extended half-life and silenced antibody-dependent cellular cytotoxicity (ADCC) function. In nonclinical studies, IMG-007 potently blocked the signalling between OX40 and OX40L. IMG-007 is being evaluated for the treatment of moderate-to-severe atopic dermatitis (AD) and severe alopecia areata (AA). In a Phase 2a study in AD patients, a short 4-week treatment with IMG-007 resulted in a rapid and marked improvement in the extent and severity of skin lesions in AD patients. Interim data from a pharmacokinetic study showed that subcutaneous IMG-007 demonstrated an exceptionally long half-life, which would enable its potential for every six months (Q6M) dosing for AD maintenance therapy. Separately, its silenced ADCC function has led to a favorable safety profile, without any reports of pyrexia and chills, differentiating it from a competing ADCC-enhanced anti-OX40 mAb. Inmagene has in-licensed IMG-007’s exclusive global rights from HUTCHMED. Forward-Looking StatementsThis press release contains forward-looking statements. While Inmagene believes the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For further information, please contact:Inmagene:Anna Vardanyan, MD, PhDSVP of Corporate and Business Developmentvardanyana@inmagenebio.com Investor Relations:Bruce MackleLifeSci Advisors, LLCbmackle@lifesciadvisors.com

BRONX, N.Y., July 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joseph Vazzana is acknowledged as a Pinnacle Life Healthcare Professional for his contributions to the field of Gastrointestinal Surgery. Continue Reading Joseph Thomas Vazzana, MD Dr. Vazzana pursued higher education at New York University where he earned a Bachelor of Science degree in Neuroscience and Psychology, minoring in Chemistry. He then attended S.U.N.Y Downstate Medical Center in Brooklyn where he received a medical degree. The doctor completed a general surgical residency at the University of Buffalo; a research fellowship in immunology and vaccination strategies for the treatment of cancer at Roswell Park Cancer Institute in Buffalo, New York; and a fellowship in minimally invasive surgery/advanced gastrointestinal surgery at Montefiore Medical Center. Dr. Vazzana is board-certified in general surgery by the American Board of Surgery (ABS) and explained that the ABS is an independent, non-profit organization located in Philadelphia, Pennsylvania, founded for the purpose of certifying surgeons who have met a defined standard of education, training, and knowledge. The doctor works within the Department of Surgery at the Montefiore Medical Center as a general surgeon and notes that it is the premier academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in the Bronx, New York City. He specializes in bariatric/foregut surgery; abdominal wall hernia repair; and colorectal surgeries and is affiliated with Montefiore Weiler Hospital; Montefiore Greene Medical Arts Pavilion; Montefiore at 1250 Waters Place; Montefiore Wakefield Campus; St. Johns Riverside Hospital Dobbs Ferry; St. Johns Riverside Hospital; and St. Johns Riverside Boyce. The doctor is highly sought after for his vast knowledge of the field and serves as an Assistant Professor within the Department of Surgery at the Albert Einstein College of Medicine, Jack and Pearl Resnick Campus. He said that general surgery is a surgical specialty that focuses on abdominal contents including the esophagus; stomach; small bowel; colon; liver; pancreas; gallbladder; appendix and bile ducts; and often the thyroid gland. As a general surgeon, Dr. Vazzana performs a wide range of abdominal surgeries for many forms of intestinal and abdominal wall neoplasms; gallbladder disease; and gastric and pancreatic disease and follows the patient through critical care and surgical recovery all the way to outpatient care. His expertise in weight reduction surgery as well as minimally invasive approaches to complex surgical disease allow him to treat the entirety of the obese surgical patient. He stated, "The obesity epidemic is growing not just in the United states but across the globe. We as surgeons need to utilize all of the tools at our disposal to handle these complex patients." His practice focuses on weight reduction surgery as a means to accomplish excellent outcomes in the morbidly obese patient across multiple general surgery conditions including but not limited to abdominal wall reconstruction (hernia repair) and colorectal surgery. Dedicated to provide the latest innovations in the field, Dr. Vazzana is a Fellow of the American College of Surgeons, American Society for Metabolic and Bariatric Surgery, and a member of the Society of Gastrointestinal Surgery. While reflecting on his career, the doctor attributes much of his success to his mentors, Norman Sas, MD; William Scott Melvin, MD; Diego Cammacho, MD; and Anibal Puente, MD. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

NEW YORK, June 6, 2024 /PRNewswire/ -- Low-income Black and Hispanic stroke survivors with uncontrolled hypertension had a more than two-fold reduction in blood pressure when they tracked it at home and sent their readings to a nurse case manager. The gains were in systolic blood pressure specifically at one year into the study and when compared to a similar group of patients who did not have access to a nurse. Led by researchers at NYU Langone, the study is the first to examine differences in home blood pressure monitoring with or without nurse case management. Further, the findings, published online June 6 in the Journal of the American Medical Association (JAMA), addressed controlling hypertension in low-income Black and Hispanic patients with stroke across multiple hospital systems. "We found that low-income Black and Hispanic patients with stroke and significant comorbidity benefit greatly from telemedicine in general, which we know ramped up during the COVID-19 pandemic," said study lead author Gbenga Ogedegbe, MD, MPH, director of the Institute for Excellence in Health Equity and professor in the Departments of Population Health and Medicine at NYU Grossman School of Medicine. "The benefit of home blood pressure telemonitoring was even more profound with the addition of nurse case management." While stroke mortality has fallen as a whole over the past ten years, Black and Hispanic patients continue to have higher rates of recurrent stroke compared to White patients. Black adults are 50 percent more likely to suffer a stroke and Black men are 70 percent more likely to die from a stroke compared to their White counterparts. Hypertension is a major risk factor for stroke, with the disparities stemming from factors such as unequal access to healthcare and effective treatments, and poorer adherence to medications. "Our goal is for enhanced telehealth programs to be implemented as standard practice for management of hypertension in this vulnerable population that is underserved and suffers adverse social determinants of health that result in unjust health disparities," said Ogedegbe. How the Study Was Conducted The research team enrolled a total of 450 low-income Black and Hispanic stroke survivors with uncontrolled hypertension and other chronic conditions from eight stroke centers across four New York City health systems (NYC Health + Hospitals, NYU Langone Health, SUNY Downstate Medical Center, and Columbia University Medical Center). Study participants were randomly assigned to either the intervention group receiving home blood pressure telemonitoring with nurse case management (enhanced telemedicine) or a control group receiving only home blood pressure telemonitoring. Seventy-two percent of all enrolled study participants had an annual household income of under $25,000. Patients in both groups received home blood pressure monitors and were instructed to take their blood pressure 12 times per week for one year. Readings were wirelessly transmitted to a web-based portal and monthly reports were sent to providers. Any reading that fell outside of an acceptable range triggered a phone call to the patient from a clinician. In addition to home blood pressure telemonitoring, patients in the intervention group also received 20 telephone counselling calls from trained nurse case managers over the course of the year. During the calls, the nurses educated patients about blood pressure, stroke symptoms and lifestyle changes (including physical activity, weight loss, nutrition and the importance of adhering to prescribed medications) that could lower blood pressure. Nurses also checked that patients were keeping up with home blood pressure monitoring, and addressed any challenges expressed by patients. The two main outcomes were patients' blood pressure after one year, and rate of recurrent stroke within two years. While both groups had a significant decline in systolic blood pressure after one year compared to baseline (with two and half times greater decline among patients in the intervention group), there was no difference in rate of recurrent stroke between the two groups at two years. Only four percent of total patients enrolled in the study had another stroke within two years (nine patients in the intervention group and nine in the control group). Ogedegbe maintains that additional studies are needed to better understand long-term clinical outcomes, cost effectiveness, and generalizability of nurse case management enhanced telehealth programs. "Our ongoing work shows the urgent need to reduce racial disparities in hypertension-related outcomes between communities of color and White patients," said Tanya M. Spruill, PhD, associate professor in the Departments of Population Health and Medicine, and the study's senior author. "We believe that telehealth programs to manage uncontrolled hypertension could play an important role in addressing structural inequities in care and substantially improve outcomes in Black and Hispanic stroke survivors." In addition to Ogedegbe, study co-authors from NYU Langone include senior author Tanya M. Spruill, PhD, Stephen K. Williams, MD; Adebayo Ogunlade, MPH; Chigozirim Izeogu, MD, McGovern Medical School at UT Health Houston; Joseph P. Eimicke, MS, Jian Kong, MS, Stephanie A. Silver, MPH, Jeanne A. Teresi, EdD, PhD, Olajide Williams, MD, Columbia University; Helen Valsamis, MD, and Susan W. Law, DO, Steven R. Levine, MD, NYC Health + Hospitals; Salina P. Waddy, MD, National Center for Advancing Translational Sciences. The research was supported by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), grant number U54 NS081765. Media Inquiries: Sasha Walek (646) 501-3873 [email protected] SOURCE NYU Langone Health